The recent FDA approval of several antitumor agents whose primary mode of action is the inhibition of VEGF receptor-2 signaling and the disruption of tumor angiogenesis (e.g. sunitinib, sorafenib) has had a profound impact on the management of patients with metastatic renal cell carcinoma (RCC). However, despite the ability of these agents to prolong PFS and in some instances, to induce partial tumor regression, the majority of RCC patients develop resistance to these agents within 6-12 months. In previous murine xenograft studies using 786-0 and A498 cell lines we have established that resistance is likely related to angiogenic escape. cDNA microarray and westerns with from xenografts of these RCC cell lines and short-term cultures (STCs) from freshly harvested human RCC identified several genes and proteins whose expression is altered with the development of resistance to sunitinib/sorafenib. These gene expression studies provide several candidate proteins/pathways that, based on their known role in tumor progression and/or angiogenesis, are likely to contribute to the development of resistance. We now propose to extend these studies to include: 1) validation of our murine tissue, blood and imaging findings in patients with RCC undergoing sunitinib therapy;2) assessment of the ability of pharmacologic inhibitors of these proteins/pathways to either delay or prevent resistance to sunitinib in subcutaneously implanted xenografts involving 786.0 and A498;3) assessment of promising combinations in subcutaneous and orthotopic xenografts using STCs and perfusion imaging. These studies will lay the groundwork for several clinical trials with sunitinib in combination with other agents selected on the basis of their ability to block one or more critical signaling pathway that might contribute to sunitinib resistance. Endpoints will include changes in tumor perfusion by MRI and serial cytokine levels, and delay in disease progression. Collectively, these studies will elucidate the mechanism by which RCC develops resistance to VEGFR blockade and identify treatment strategies that might circumvent this problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-08
Application #
8322742
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
8
Fiscal Year
2011
Total Cost
$249,028
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Gopal, Raj K; Kübler, Kirsten; Calvo, Sarah E et al. (2018) Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell 34:242-255.e5
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Signoretti, Sabina; Flaifel, Abdallah; Chen, Ying-Bei et al. (2018) Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol :JCO2018792259
Hamieh, Lana; Choueiri, Toni K; Ogórek, Barbara et al. (2018) Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet 14:e1007679
Gao, Xin; McDermott, David F (2018) Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Biol Ther 18:947-957
Gopal, Raj K; Calvo, Sarah E; Shih, Angela R et al. (2018) Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. Proc Natl Acad Sci U S A 115:E6283-E6290
Scelo, Ghislaine; Muller, David C; Riboli, Elio et al. (2018) KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. Clin Cancer Res 24:5594-5601
Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95
Gao, Xin; Jegede, Opeyemi; Gray, Connor et al. (2018) Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 16:341-348
Liu, Wenjing; Chen, Binbin; Wang, Yang et al. (2018) RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proc Natl Acad Sci U S A 115:E1475-E1484

Showing the most recent 10 out of 153 publications